Lantern Pharma (LTRN) Investor update summary

Platform strategy and capabilities

• Open Medicine spun out as a separate entity in 2026 with selected assets, IP and capabilities; the platform grew from internal drug-development needs and supports disease-focused analysis, hypothesis generation and validation.

• First commercialized as withZeta.ai in April 2026, the platform is expanding from rare cancers and oncology into broader diseases, therapies and drug-development stages; Zeta Omics adds a computational biology module.

• Multi-agent AI supports parallel hypothesis testing and recursive reasoning, combining curated knowledge bases, regulatory constraints, real-world data and specialized tools to generate actionable insights and reduce false results.

• AI co-scientists draw on real clinical data and oncology decision points; demonstrations included ferroptosis-based cancer ranking, drug-vulnerability validation, rare-disease biomarker prioritization and molecule design, with proposed mechanisms and molecules requiring further validation.

Adoption and product roadmap

• Open Medicine had over 200 users, with monthly growth; power users generated several dozen interactions weekly, and a handful of customers generated hundreds of molecules.

• Users include biopharma R&D teams, academic and translational labs, CROs, service providers, independent developers and financial institutions; requests include proprietary data, collaboration, on-premise access, parallel agents and deeper trial-design support.

• Mobile functionality launched weeks earlier, followed by significant increases in some user groups; security, scalability, costs and performance benchmarks are also being developed.

• Roadmap includes neurodegenerative, immune, inflammatory, cardio-metabolic and psychedelic areas; new modalities, trial-design and regulatory tools, portfolio intelligence, and social and enterprise features.

• Discussions span biopharma, patient groups, CROs, financial institutions, academic consortia and regulatory agencies, including co-development and integration; advisory recruitment and customer feedback guide development.

Market and commercialization

• Management estimated current market spend at $4.5B-$5B, with agentic AI still a small portion; it expects legacy software and services to be disrupted by agentic delivery.

• Management estimated $3.8B of software and service revenue could be flat to negative, with $1.5B-$2B shifting to agentic delivery; a separate estimate projects AI drug-R&D revenue rising from $4.65B in 2025 to $10.6B by 2030.

• Revenue options include subscriptions, freemium access, enterprise and software licensing, success-based fees, revenue sharing, co-development and embedding the platform in service-provider workflows.

• Larger pharma and enterprise deals are a focus; subscription prices are expected to rise next quarter, alongside development of additional revenue sources.